Regeneron Pharmaceuticals Inc. Stock Advances 13.3%, Outperforms Peers
Dow Jones2026/10/30 20:33This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Regeneron Pharmaceuticals Inc. climbed 13.3% to $927.89 on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 1.8% to 7,580.07 and Dow Jones Industrial Average falling 1.1% to 51,770.31.
This was the stock's second consecutive day of gains.
Regeneron Pharmaceuticals Inc. hit a new 52-week high, surpassing its previous peak of $859.34, which the company reached on September 3rd.
The stock outperformed some of its peers, as Amgen Inc. rose 1.1% to $466.01, Moderna Inc. fell 0.5% to $221.72, and Gilead Sciences Inc. rose 3.06% to $170.68.
Trading volume totaled 2.8 million, compared to the 50-day average of 687,250.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 30, 2026 16:33 ET (20:33 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
